Literature DB >> 7281492

Malignant lymphoma of true histiocytic origin: histiocytic sarcoma. A morphological, ultrastructural, immunological, cytochemical and clinical study of 10 cases.

P van der Valk, J te Velde, J Jansen, D J Ruiter, P J Spaander, C J Cornelisse, C J Meijer.   

Abstract

Ten tumors of true histiocytic origin (Histiocytic Sarcoma) are presented. The tumor cells were identified as histiocytes by immunological, cytochemical and ultrastructural criteria (cytoplasmic lysozyme activity, presence of C3 and Fc gamma receptor, strong acid phosphatase and alpha-naphthyl acetate esterase activity, presence of lysosomes, absence of cell junctions and evidence of phagocytosis). The tumors identified in this way showed the following histological characteristics: diffuse proliferation of large tumor cells with ample cytoplasm, containing granular or occasionally diffuse diastase resistant PAS positive material, erythrophagocytosis, and haemosiderin pigment. The large or enormous nuclei were irregular, with occasional deep indentations, sharply defined nuclear membrane, coarse chromatin and conspicuous nucleoli. Despite the uniformity of these criteria differences in presence of alpha 1-antitrypsin, alpha 1-antichymotrypsin and 5 Nucleotidase activity and the number of lysosomes in the cytoplasm were found. The findings are suggestive of a spectrum of cytological in these Histiocytic Sarcomas. The clinical picture ranged from monolocalization in a lymphoid organ to that of a diffuse Malignant Histiocytosis. The relationship between good response to therapy and complete remission and the absence of alpha 1-antitrypsin and a high number of lysosomes is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7281492     DOI: 10.1007/BF00709158

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histol        ISSN: 0340-1227


  31 in total

1.  The distribution of muramidase (lysozyme) in human tissues.

Authors:  D Y Mason; C R Taylor
Journal:  J Clin Pathol       Date:  1975-02       Impact factor: 3.411

2.  The study of enzymes in tissue sections.

Authors:  G GOMORI
Journal:  Am J Clin Pathol       Date:  1946-06       Impact factor: 2.493

3.  New approaches to the classification of the lymphomata.

Authors:  R J Lukes; R D Collins
Journal:  Br J Cancer Suppl       Date:  1975-03

4.  A modified method for tissue localization of cells bearing a complement receptor.

Authors:  C J Meijer; J Lindeman
Journal:  J Immunol Methods       Date:  1975-11       Impact factor: 2.303

5.  Methyl-methacrylate as an embedding medium in histopathology.

Authors:  J T Velde; R Burkhardt; K Kleiverda; L Leenheers-Binnendijk; W Sommerfeld
Journal:  Histopathology       Date:  1977-09       Impact factor: 5.087

6.  [Seminar for hematologic-cytochemical techniques (author's transl)].

Authors:  L D Leder; H J Stutte
Journal:  Verh Dtsch Ges Pathol       Date:  1975

7.  Characteristics of mononuclear cell populations in chronically inflamed synovial membranes.

Authors:  C J Meijer; L B van de Putte; F Eulderink; R Kleinjan; G Lafeber; G T Bots
Journal:  J Pathol       Date:  1977-01       Impact factor: 7.996

8.  Primary gastrointestinal lymphomas: a classification of 66 cases.

Authors:  P Isaacson; D H Wright; M A Judd; B L Mepham
Journal:  Cancer       Date:  1979-05       Impact factor: 6.860

9.  Malignant histiocytosis of the intestine. Its relationship to malabsorption and ulcerative jejunitis.

Authors:  P Isaacson; D H Wright
Journal:  Hum Pathol       Date:  1978-11       Impact factor: 3.466

Review 10.  A review of histiocytosis X with particular reference to eosinophilic granuloma of the lung.

Authors:  B Corrin; F Basset
Journal:  Invest Cell Pathol       Date:  1979 Jul-Sep
View more
  10 in total

1.  Lymphomas of true histiocytic origin. Expression of different phenotypes in so-called true histiocytic lymphoma and malignant histiocytosis.

Authors:  S M Hsu; Y S Ho; P L Hsu
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

2.  Malignant lymphoma of the gastrointestinal tract and mesentery. A clinico-pathologic study of the significance of histologic classification. NHL Study Group of the Comprehensive Cancer Center West.

Authors:  J H van Krieken; R Otter; J Hermans; K van Groningen; P J Spaander; M M van de Sandt; J F Keuning; P M Kluin
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

3.  Characterization of B-cell non-Hodgkin's lymphomas. A study using a panel of monoclonal and heterologous antibodies.

Authors:  P van der Valk; J Jansen; M R Daha; C J Meijer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

4.  Malignant lymphomas.

Authors:  B H Tindle
Journal:  Am J Pathol       Date:  1984-07       Impact factor: 4.307

5.  Morphometric characterisation of 52 B cell non-Hodgkin's lymphomas.

Authors:  P van der Valk; A Mosch; P J Kurver; C J Meijer
Journal:  J Clin Pathol       Date:  1983-03       Impact factor: 3.411

6.  Morphometric characterization of diffuse large-cell (histiocytic) lymphomas.

Authors:  P van der Valk; J Hermans; R Brand; C J Cornelisse; P J Spaander; C J Meijer
Journal:  Am J Pathol       Date:  1982-06       Impact factor: 4.307

7.  Ultrastructural identification of neoplastic histiocytes--monocytes: an application of a newly developed cytochemical technique.

Authors:  H Kim; G A Pangalis; B C Payne; M E Kadin; H Rappaport
Journal:  Am J Pathol       Date:  1982-02       Impact factor: 4.307

8.  Lymphomatoid papulosis and Hodgkin's disease: are they related?

Authors:  R Willemze; E Scheffer; W A Van Vloten; C J Meijer
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

9.  Analysis of large-cell lymphomas using monoclonal and heterologous antibodies.

Authors:  P van der Valk; G van den Besselaar-Dingjan; M R Daha; C J Meijer
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

10.  EBM/11 reactivity in malignant histiocytosis.

Authors:  P M Kelly; M McGovern; K C Gatter; J M Theaker; J O McGee
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.